VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Pathogen Page
Mycobacterium tuberculosis

Table of Contents

  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. Ag85B from M. tuberculosis H37Rv
    2. Apa
    3. bfrA
    4. DnaK
    5. drrC
    6. EsxA (ESAT-6)
    7. EsxB
    8. esxV
    9. esxW
    10. fadD26
    11. FbpA (Ag85A)
    12. FbpD
    13. HBHA
    14. KatG
    15. leuD
    16. lysA
    17. mce-2
    18. mce-3
    19. Mpt63
    20. MPT64
    21. MPT83
    22. Mtb72F
    23. panC
    24. panD
    25. PE20
    26. PepA
    27. PhoP
    28. PPE14
    29. PPE18
    30. PPE31
    31. PPE42
    32. proC
    33. PstS1
    34. PstS3
    35. RD1
    36. Rv1813c
    37. Rv2660c
    38. SecA2
    39. sigE
    40. sigF
    41. SodA
    42. trpD
    43. xyzzy
  3. Vaccine Related Host Genes
    1. APOBEC3B
    2. C19orf66
    3. CD70
    4. Cxcl10
    5. Cxcl11
    6. Cxcl9
    7. Defb3
    8. Defb4
    9. Ebi3
    10. Fth1
    11. Ftl
    12. GPR182
    13. GPX1
    14. HIST1H2BE
    15. HIST2H4A
    16. human IFNG
    17. IFNG
    18. Ifng (Interferon gamma)
    19. IL-1b
    20. IL-6
    21. IL10
    22. IL10
    23. Il10 (interleukin 10)
    24. Il12b
    25. Il15
    26. Il17f
    27. IL2
    28. Il2
    29. Il4 (interleukin 4)
    30. IL6
    31. lipY
    32. Ltf
    33. Nos2
    34. PCDHB1
    35. PTCD1
    36. SLC11A1
    37. STAG3
    38. TBX21
    39. TLR1
    40. TNF-alpha
    41. TSC22D4
  4. Vaccine Information
    1. Ag85B and ESAT-6 fusion protein
    2. Arabinomannan-tetanus toxoid conjugate
    3. attenuated M. bovis strain WAg539
    4. Bacille Calmette-Guérin (BCG)
    5. BCG auxotroph expressing HIV-1 clade immunogen
    6. BCG expressing MSP
    7. BCG mutant secreting listeriolysin
    8. BCG Vaccine
    9. BCG Vaccine (Freeze-Dried)
    10. BCG-DHTM
    11. DNA vaccine co-expressing A85A and caspase-3
    12. DNA vaccine Rv1806-1807
    13. ID93/GLA-SE
    14. ΔureC hly+ rBCG
    15. LT-BCG- Ag85B /Rv3425
    16. M. bovis WAg520 strain
    17. M. bovis WAg522 strain
    18. M. tuberculosis DNA vaccine (containing the ESAT-6, MPT-64, MPT-83, and KatG constructs)
    19. M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting
    20. M. tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag
    21. M. tuberculosis DNA Vaccine encoding Ag85B Protein
    22. M. tuberculosis DNA vaccine encoding Ag85B, MPT64 and MPT83
    23. M. tuberculosis DNA Vaccine encoding KatG
    24. M. tuberculosis DNA vaccine ESAT-6
    25. M. tuberculosis DNA vaccine pAK4-sod
    26. M. tuberculosis DNA vaccine pcDNA3.1+/Ag85A DNA encoding Ag85A
    27. M. tuberculosis HBHA Protein Vaccine
    28. M. tuberculosis Mtb72F Protein Subunit Vaccine
    29. M. tuberculosis phoP mutant SO2
    30. M. tuberculosis secA2 mutant
    31. M.S-Δesx-3-IKEPLUS (M. tuberculosis)
    32. Mtb72f fusion protein
    33. MVA/IL-15/5Mtb vaccine
    34. MVA85A prime and BCG boost
    35. Mycobacterium tuberculosis DeltasigF mutant vaccine
    36. Mycobacterium tuberculosis drrC mutant vaccine
    37. Mycobacterium tuberculosis fadD26 mutant vaccine
    38. Mycobacterium tuberculosis leuD mutant vaccine
    39. Mycobacterium tuberculosis lysA/secA2 mutant vaccine
    40. Mycobacterium tuberculosis mce-2 mutant vaccine
    41. Mycobacterium tuberculosis mce-3 mutant vaccine
    42. Mycobacterium tuberculosis panCD mutant vaccine
    43. Mycobacterium tuberculosis proC mutant vaccine
    44. Mycobacterium tuberculosis RD1/panCD mutant vaccine
    45. Mycobacterium tuberculosis sigE mutant vaccine
    46. Mycobacterium tuberculosis trpD mutant vaccine
    47. Mycobax
    48. rBCG-Ag85A/ Ag85B
    49. rBCG-Ag85A[Tokyo]
    50. rBCG-LTAK63
    51. recombinant S. typhimurium secreting M. tuberculosis ESAT-6
  5. References
I. General Information
1. NCBI Taxonomy ID:
1773
2. Disease:
Tuberculosis
3. Introduction
At the end of 19th century, Robert Koch discovered that Mycobacterium tuberculosis was the causative agent of tuberculosis (TB). TB is a major cause of morbidity and mortality throughout the world despite more than a half century of widespread vaccination, claiming millions of lives every year. The extraordinary high prevalence of the latent infection [estimated at one-third of the world's population] is one of the main factors contributing to the high incidence of active tuberculosis. The other factor is convergence of the TB and HIV epidemics. With HIV/AIDS fueling the TB crisis, the WHO has estimated that more than 1 billion people will be infected with TB bacilli in the next 20 years (Gupta et al., 2007).
M. tuberculosis are Gram-positive bacilli lacking both flagella and capsules. M. tuberculosis is preferentially established in the pulmonary system in a dormant state after initial infection via aerosol transmission. The M. tuberculosis complex, a group of Mycobacterium including M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, and M. microti, are tuberculosis-inducing bacteria which have low horizontal gene transfer and variable levels of virulence (Ducati et al., 2006).
4. Microbial Pathogenesis
Mouse and guinea pig models have been used extensively to understand the host and pathogen-specific factors controlling pathogenesis of tuberculosis. Transmission of M. tuberculosis via intravenous route in murine models is followed by initial bacterial replication and subsequent macrophage activation via IL-6, IL-12, and TNF-mediated mechanisms. Bacterial load is significantly reduced at 2 weeks post-infection in liver and spleen. After load reduction, selected lymphocytes are activated which can then induce macrophages to begin producing nitric oxide via the iNOS pathway. Bacteria which survive the initial clearance by the host enter a viable yet non-replicating persistence stage. Factors such as immune suppression from aging, iNOS inhibition, and corticosteroid therapy can shift the dormant bacilli back into a replicative state. As an example of preferred host niche, transmission via inhalation will sometimes result in bacilli establishing infection in macrophage phagosomes in the lung. These macrophages become lodged in the calcified tubercles, and can later initiate formation of granulomas through a CD4-mediated delayed-type hypersensitivity reaction. Each granuloma can remain dormant, reduce in size and possibly disappear, initiate progressive interstitial fibrosis in lung tissue, and/or necrotize (Ernst et al., 2007). Similar mechanisms are observed in liver tissue (Ducati et al., 2006).
Numerous pathogen- and host-specific factors related to pathogenesis of tuberculosis are potential vaccine targets. For example, the Bacille-Calmette Guiren (BCG) vaccine was obtained from an M. bovine strain which lost its virulence after 39 passages (Ducati et al., 2006). Evidence from subtractive hybridization experiments, along with whole-genome microarrays and BAC arrays and other experimental evidence, suggests that the RD1 locus is the main virulence feature that is absent from 13 strains of avirulent BCG yet present in hundreds of other M. tuberculosis strains (Ernst et al., 2007). RD1 is related to the regulation of the early secreted antigen 6 kDa [ESAT-6] secretion system 1[ESX-1], an important pathway which is linked to the recruitment and infection of macrophages to initially infected sites and subsequent disease propagation (Ernst et al., 2007).
5. Host Ranges and Animal Models
Host ranges extend to many animals, including human, mouse, guinea pig, rabbit, and cattle. The most predominant animal used to study M. tuberculosis for virulence assessment and vaccine development is likely the mouse, which include C57BL/6 and BALB/c strains, mainly due to cost effectiveness for long-term vaccination/challenge studies. Dunkin Hartley guinea pigs are often used in M. tuberculosis studies as a close model for the overall pathogenesis in humans.
6. Host Protective Immunity
Although it is known that IFN-gamma is essential for protective immunity, animal and human studies have found that IFN-gamma alone is not sufficient for the prevention of TB disease. There is evidence that IL-23, a recently described member of the IL-12 family of cytokines, is important in the immuno-pathogenesis of TB. There is also evidence that regulatory T cells (Treg) are present in TB disease and that Treg may suppress effector T cell responses (Fletcher, 2007). New vaccines seek to target specific CD1, CD4+, and CD8+ T and B cell responses to assist in eradicating the disease via improved clearance of infected cells and bacterial loads.
Loading...
Loading Pathogen Genes...
Loading...
Loading Host Genes...
Loading...
Loading Vaccines...
Loading References...